Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma.
Lazzarino M, Corso A, Barbarano L, Alessandrino EP, Cairoli R, Pinotti G, Ucci G, Uziel L, Rodeghiero F, Fava S, Ferrari D, Fiumanò M, Frigerio G, Isa L, Luraschi A, Montanara S, Morandi S, Perego D, Santagostino A, Savarè M, Vismara A, Morra E. Lazzarino M, et al. Among authors: fava s. Bone Marrow Transplant. 2001 Nov;28(9):835-9. doi: 10.1038/sj.bmt.1703240. Bone Marrow Transplant. 2001. PMID: 11781643
The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
Corso A, Barbarano L, Zappasodi P, Cairoli R, Alessandrino EP, Mangiacavalli S, Ferrari D, Fava S, Fiumanò M, Frigerio G, Isa L, Luraschi A, Klersy C, De Paoli A, Vergani C, Banfi L, Perego D, Ucci G, Pinotti G, Savarè M, Uziel L, Vismara A, Morra E, Lazzarino M. Corso A, et al. Among authors: fava s. Haematologica. 2004 Sep;89(9):1124-7. Haematologica. 2004. PMID: 15377474 Clinical Trial.
5-year results of cisplatin-epirubicin-vinorelbine (PEV) combination as primary chemotherapy in T2-3, N0-2 breast cancer patients: a multicentre phase II study.
Barni S, Visini M, Piazza E, Ionta MT, Ardizzoia A, Arnoldi E, Fava S, Pinotti G, Torretta F, Corradini G, Villa S, Nosenzo AM, Massidda B, Cazzaniga ME. Barni S, et al. Among authors: fava s. Anticancer Res. 2007 Jul-Aug;27(4C):3019-24. Anticancer Res. 2007. PMID: 17695490 Free article. Clinical Trial.
Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer. Cooperative Group of Study and Treatment of Breast Cancer.
Riccardi A, Brugnatelli S, Giordano M, Danova M, Pugliese P, Tinelli C, Klersy C, Richetti A, Fava S, Nastasi G, Rinaldi E, Fregoni V, De Monte A, Trotti G, Bovio A, Ascari E. Riccardi A, et al. Among authors: fava s. Tumori. 1998 Sep-Oct;84(5):540-6. doi: 10.1177/030089169808400506. Tumori. 1998. PMID: 9862513 Clinical Trial.
A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01).
Riccardi A, Pugliese P, Danova M, Brugnatelli S, Grasso D, Giordano M, Bernardo G, Giardina G, Fava S, Montanari G, Pedrotti C, Trotti G, Rinaldi E, Poli MA, Tinelli C. Riccardi A, et al. Among authors: fava s. Br J Cancer. 2001 Jul 20;85(2):141-6. doi: 10.1054/bjoc.2001.1897. Br J Cancer. 2001. PMID: 11461067 Free PMC article. Clinical Trial.
145 results